lilly glp-1 drug lowers self-pay prices of single-dose Zepbound vials Lilly hikes revenue forecast by

In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

For best results, we recommend 3-6 months of consistent daily use

Vegetarian capsules with chlorophyll, no artificial additives

We used version 2 of the Cochrane risk-of-bias tool for randomised trials to assess risk of bias for the primary outcome

GLP-1RA only reduced the risk of nonfatal stroke